drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (CAR T cells)
drug_description
Autologous, gene-modified T cells expressing an FMC63-derived anti-CD19 scFv with CD8 hinge, TNFRSF19 transmembrane, 4-1BB costimulatory, and CD3ζ signaling domains; designed to recognize CD19 on malignant B cells and mediate T-cell activation, proliferation, and cytotoxic killing.
nci_thesaurus_concept_id
C176018
nci_thesaurus_preferred_term
Anti-CD19 CAR T Cells Preparation
nci_thesaurus_definition
Any preparation of CAR-T cells that targets CD19.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-modified to express a CD19-directed CAR (FMC63 scFv, CD8 hinge, TNFRSF19 transmembrane, 4-1BB costimulatory, CD3ζ signaling). Upon binding CD19 on malignant B cells, the CAR triggers T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated cytotoxic killing, leading to targeted elimination of CD19+ cells and potential persistence for ongoing immune surveillance.
drug_name
Anti-CD19 CAR-T cells
nct_id_drug_ref
NCT06227026